Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumors, Adult

In brief

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

Key facts

Study ID

NCT06504368

Run by

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

People needed

32

Starts

2024-05-29

Expected to finish

2027-12-31

Last updated by the study team

2025-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adults, aged greater than or equal to (≥) 18 years.
• Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma
• that is refractory to standard therapy known to provide clinical benefit for their condition OR
• have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR
• have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR
• for which no standard therapy is available
• Measurable disease according to RECIST version 1.1.
• Malignancy not currently amenable to surgical intervention.
• ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent.
• Other protocol defined inclusion criteria could apply

You may not qualify if…

• Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.
• Other protocol defined exclusion criteria could apply

Where it is running

• NEXT Oncology — Irving, Texas, United States (enrolling)
• Next Oncology — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.